Maternal HIV-1 antibody and vertical transmission in subtype C virus infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 5, 2002, Pages 435-440

  Guevara, Hugo ^a   Casseb, Jorge ^a   Zijenah, Lynn S ^a   Mbizvo, Michael ^a   Oceguera III, Leopoldo F ^a   Hanson, Carl V ^a   Katzenstein, David A ^a   Hendry, R Michael ^a  

^a PFIZER INC   (United States)

Author keywords

Envelope antibody; HIV 1 subtype C; Vertical transmission

Indexed keywords

ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN V3; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RISK; SEQUENCE HOMOLOGY; VERTICAL TRANSMISSION; VIRUS ENVELOPE; VIRUS LOAD;

EID: 0036232658     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200204150-00002     Document Type: Article

References (43)

1. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1
2. Mother-to-infant transmission of human immunodeficiency virus type 1: Association with prematurity or low anti-gp120
3. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers
4. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain
5. Maternofetal transmission of human immunodeficiency virus-1: The role of antibodies to the V3 primary neutralizing domain
6. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study
7. Lack of association between maternal antibodies to V3 loop peptides and maternal-infant HIV-1 transmission
8. Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus
9. Lack of association between anti-V3 loop antibody and perinatal HIV-1 transmission in Kinshasa, Zaire, despite use of assays based on local HIV-1 strains
10. Vertical transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies
11. Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand
12. Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women
13. Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer
14. Mortality in the first two years among infants born to HIV-infected women in Harare, Zimbabwe
15. Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe
16. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1
17. HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe
18. Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers
19. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type I sensitive to neutralization by vaccine sera
20. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand
21. The effect of maternal viral load on the risk of perinatal transmission of HIV-1
22. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
23. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gpl20 molecule
24. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
25. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
26. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS Clinical Trials Group protocol 273)
27. Direct enzyme-linked immunosorbent assay of anti-peptide antibodies using capture of biotinylated peptides by immobilized avidin
28. Effective method for synthetic peptide immobilization that increases the sensitivity and specificity of ELISA procedures
29. Rapid diagnosis of hantavirus disease with an IgG-avidity assay
30. Measurement of avidity of specific IgG for verification of recent primary rubella
31. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity
32. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1
33. Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates
34. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections
35. Features of HIV-1 that could influence maternal-child transmission
36. Geographic diversity of human immunodeficiency virus type 1: Serologic reactivity to env epitopes and relationship to neutralization
37. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas
38. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies
39. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
40. Genetic analysis of viral variants selected in transmission of human immunodeficiency viruses to newborns
41. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum
42. Prenatal transmission of subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood